CSIMarket
 


Liminal Biosciences Inc   (LMNL)
Other Ticker:  
 

Liminal Biosciences Inc 's Long Term Debt to Equity

LMNL's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


In the forth quarter 2022 Liminal Biosciences Inc did not have Long Term Debt.

Within Major Pharmaceutical Preparations industry Liminal Biosciences Inc achieved the lowest Long Term Debt to Equity in the forth quarter 2022. While total ranking remained the same in the forth quarter 2022 compared to the previous quarter at no. .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt LMNLīs has?
What is the structure of LMNLīs Equity?


LMNL Long Term Debt to Equity (Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Equity Change 6.87 % 6.87 % 6.87 % 6.87 % 125.69 %
Y / Y Long Term Debt Change - - - - -68.69 %
Long Term Debt to Equity MRQ - - - - 0
LMNL's Total Ranking # # # # #
Seq. Equity Change 0 % 0 % 0 % 6.87 % 0 %
Seq. Long Term Debt Change - - - - 0 %



Long Term Debt to Equity forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Liminal Biosciences Inc 's Equity $ 28 Millions Visit LMNL's Balance sheet
Liminal Biosciences Inc 's Long Term Debt $ 0 Millions Visit LMNL's Balance sheet
Source of LMNL's Sales Visit LMNL's Sales by Geography


Cumulative Liminal Biosciences Inc 's Long Term Debt to Equity

LMNL's Long Term Debt to Equity for the trailling 12 Months

LMNL Long Term Debt to Equity

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Equity TTM Growth 6.87 % 6.87 % 6.87 % 6.87 % 125.69 %
Y / Y Long Term Debt TTM Growth - - - - -68.69 %
Long Term Debt to Equity TTM - 0 0 0 0
Total Ranking TTM
Seq. Equity TTM Growth 0 % 0 % 0 % 6.87 % 0 %
Seq. Long Term Debt TTM Growth - - - - 0 %


On the trailing twelve months basis During the twelve months ending IV Quarter 2022 Liminal Biosciences Inc did not have Long Term Debt .
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry LMNL recorded the lowest Long Term Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 0.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt LMNLīs has?
What is the structure of LMNLīs Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market #


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Long Term Debt to Equity in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Long Term Debt to EquityDec 31 2022 MRQ Long Term DebtDec 31 2022 MRQ Equity

Date modified: 2023-03-24T14:51:44+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com